The development of an effective vaccine has been hindered by the enormous diversity of
human immunodeficiency virus‐1 (HIV‐1) and its ability to escape a myriad of host immune …

HIV-1 is transmitted by sexual contact across mucosal surfaces, by maternal-infant
exposure, and by percutaneous inoculation. For reasons that are still incompletely …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …

During HIV-1 infection, antibodies are generated against the region of the viral gp120
envelope glycoprotein that binds CD4, the primary receptor for HIV-1. Among these …

INTRODUCTION A major goal of HIV-1 vaccine development is to identify immunogens
capable of inducing protective titers of broadly neutralizing antibodies (bNAbs) against …

Identification of full-length transmitted HIV-1 genomes could be instrumental in HIV-1
pathogenesis, microbicide, and vaccine research by enabling the direct analysis of those …

The restricted neutralization breadth of vaccine-elicited antibodies is a major limitation of
current human immunodeficiency virus-1 (HIV-1) candidate vaccines. In order to permit the …

Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are
complicated by the genetic and antigenic variability of the viral envelope glycoproteins …

An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals
is needed to guide vaccine design and immunization strategies. Here we used a large panel …

Abstract Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal
antibodies are currently under development to treat and prevent HIV-1 infection. We …